Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1992 Jul;216(1):27–34. doi: 10.1097/00000658-199207000-00005

The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease.

N Y Tse 1, C K Hoh 1, R A Hawkins 1, M J Zinner 1, M Dahlbom 1, Y Choi 1, J Maddahi 1, F C Brunicardi 1, M E Phelps 1, J A Glaspy 1
PMCID: PMC1242543  PMID: 1632699

Abstract

Positron emission tomography (PET) is a computer-aided tomographic imaging technique that uses positron-emitting compounds to trace biochemical processes of tissue, and construct images based on them. The authors applied a whole-body PET imaging technique to patients with breast masses or mammographic abnormalities using the isotope 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG), in a clinical trial to evaluate the feasibility of using PET to identify primary breast cancer, axillary lymph node involvement, and systemic metastases, before surgical resection. Fourteen patients have been entered on this study, 10 of whom proved to have breast cancer. Positron emission tomography correctly predicted the nature of 12 of the 14 primary breast lesions, and correctly determined the lymph node status of 11 of the 14 patients. The authors conclude that PET with FDG has potential as a diagnostic modality for detection of primary breast cancer, particularly in the patient with radiodense breasts by conventional mammography, and that it has potential for the preoperative identification of axillary lymph node metastases.

Full text

PDF
27

Images in this article

30FIG. 1.
on p.30
30FIG. 2.
on p.30
31FIG. 3.
on p.31

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler L. P., Blair H. F., Makley J. T., Williams R. P., Joyce M. J., Leisure G., al-Kaisi N., Miraldi F. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991 Aug;32(8):1508–1512. [PubMed] [Google Scholar]
  2. Adler L. P., Blair H. F., Williams R. P., Pathria M. N., Makley J. T., Joyce M. J., al-Kaisi N., Miraldi F. Grading liposarcomas with PET using [18F]FDG. J Comput Assist Tomogr. 1990 Nov-Dec;14(6):960–962. doi: 10.1097/00004728-199011000-00017. [DOI] [PubMed] [Google Scholar]
  3. Alavi J. B., Alavi A., Chawluk J., Kushner M., Powe J., Hickey W., Reivich M. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 1988 Sep 15;62(6):1074–1078. doi: 10.1002/1097-0142(19880915)62:6<1074::aid-cncr2820620609>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Chu K. C., Smart C. R., Tarone R. E. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst. 1988 Sep 21;80(14):1125–1132. doi: 10.1093/jnci/80.14.1125. [DOI] [PubMed] [Google Scholar]
  5. Di Chiro G., DeLaPaz R. L., Brooks R. A., Sokoloff L., Kornblith P. L., Smith B. H., Patronas N. J., Kufta C. V., Kessler R. M., Johnston G. S. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982 Dec;32(12):1323–1329. doi: 10.1212/wnl.32.12.1323. [DOI] [PubMed] [Google Scholar]
  6. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol. 1987 May;22(5):360–371. doi: 10.1097/00004424-198705000-00002. [DOI] [PubMed] [Google Scholar]
  7. Haberkorn U., Strauss L. G., Dimitrakopoulou A., Engenhart R., Oberdorfer F., Ostertag H., Romahn J., van Kaick G. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991 Aug;32(8):1485–1490. [PubMed] [Google Scholar]
  8. Kern K. A., Brunetti A., Norton J. A., Chang A. E., Malawer M., Lack E., Finn R. D., Rosenberg S. A., Larson S. M. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med. 1988 Feb;29(2):181–186. [PubMed] [Google Scholar]
  9. Kim C. K., Alavi J. B., Alavi A., Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol. 1991 Feb;10(1):85–91. doi: 10.1007/BF00151249. [DOI] [PubMed] [Google Scholar]
  10. Kubota K., Matsuzawa T., Amemiya A., Kondo M., Fujiwara T., Watanuki S., Ito M., Ido T. Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr. 1989 Nov-Dec;13(6):1097–1098. [PubMed] [Google Scholar]
  11. Minn H., Joensuu H., Ahonen A., Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988 May 1;61(9):1776–1781. doi: 10.1002/1097-0142(19880501)61:9<1776::aid-cncr2820610909>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  12. Minn H., Paul R., Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1988 Sep;29(9):1521–1525. [PubMed] [Google Scholar]
  13. Minn H., Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15(2):61–66. doi: 10.1007/BF00702620. [DOI] [PubMed] [Google Scholar]
  14. Nolop K. B., Rhodes C. G., Brudin L. H., Beaney R. P., Krausz T., Jones T., Hughes J. M. Glucose utilization in vivo by human pulmonary neoplasms. Cancer. 1987 Dec 1;60(11):2682–2689. doi: 10.1002/1097-0142(19871201)60:11<2682::aid-cncr2820601118>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  15. Ogawa T., Uemura K., Shishido F., Yamaguchi T., Murakami M., Inugami A., Kanno I., Sasaki H., Kato T., Hirata K. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr. 1988 Mar-Apr;12(2):290–297. doi: 10.1097/00004728-198803000-00019. [DOI] [PubMed] [Google Scholar]
  16. Padgett H. C., Schmidt D. G., Luxen A., Bida G. T., Satyamurthy N., Barrio J. R. Computer-controlled radiochemical synthesis: a chemistry process control unit for the automated production of radiochemicals. Int J Rad Appl Instrum A. 1989;40(5):433–445. doi: 10.1016/0883-2889(89)90213-x. [DOI] [PubMed] [Google Scholar]
  17. Patronas N. J., Brooks R. A., DeLaPaz R. L., Smith B. H., Kornblith P. L., Di Chiro G. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR Am J Neuroradiol. 1983 May-Jun;4(3):533–535. [PMC free article] [PubMed] [Google Scholar]
  18. Patronas N. J., Di Chiro G., Kufta C., Bairamian D., Kornblith P. L., Simon R., Larson S. M. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985 Jun;62(6):816–822. doi: 10.3171/jns.1985.62.6.0816. [DOI] [PubMed] [Google Scholar]
  19. Phillips P. C., Dhawan V., Strother S. C., Sidtis J. J., Evans A. C., Allen J. C., Rottenberg D. A. Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol. 1987 Jan;21(1):59–63. doi: 10.1002/ana.410210111. [DOI] [PubMed] [Google Scholar]
  20. Strauss L. G., Clorius J. H., Schlag P., Lehner B., Kimmig B., Engenhart R., Marin-Grez M., Helus F., Oberdorfer F., Schmidlin P. Recurrence of colorectal tumors: PET evaluation. Radiology. 1989 Feb;170(2):329–332. doi: 10.1148/radiology.170.2.2783494. [DOI] [PubMed] [Google Scholar]
  21. Strauss L. G., Conti P. S. The applications of PET in clinical oncology. J Nucl Med. 1991 Apr;32(4):623–650. [PubMed] [Google Scholar]
  22. Swets J. A. Measuring the accuracy of diagnostic systems. Science. 1988 Jun 3;240(4857):1285–1293. doi: 10.1126/science.3287615. [DOI] [PubMed] [Google Scholar]
  23. Verbeek A. L., Hendriks J. H., Holland R., Mravunac M., Sturmans F., Day N. E. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet. 1984 Jun 2;1(8388):1222–1224. doi: 10.1016/s0140-6736(84)91703-3. [DOI] [PubMed] [Google Scholar]
  24. WARBURG O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309–314. doi: 10.1126/science.123.3191.309. [DOI] [PubMed] [Google Scholar]
  25. Wahl R. L., Cody R. L., Hutchins G. D., Mudgett E. E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991 Jun;179(3):765–770. doi: 10.1148/radiology.179.3.2027989. [DOI] [PubMed] [Google Scholar]
  26. Wahl R. L., Cody R., Hutchins G., Mudgett E. Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose. N Engl J Med. 1991 Jan 17;324(3):200–200. doi: 10.1056/NEJM199101173240317. [DOI] [PubMed] [Google Scholar]
  27. Weber G. Enzymology of cancer cells (second of two parts). N Engl J Med. 1977 Mar 10;296(10):541–551. doi: 10.1056/NEJM197703102961005. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES